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A variable neurodegenerative
phenotype with polymerase c
mutation
Deficiency of mitochondrial DNA polymer-
ase c (POLG), which is responsible for
mtDNA replication and repair, causes mito-
chondrial diseases including autosomal
dominant progressive external ophthalmo-
plegia (PEO),1 childhood hepato-encephalo-
pathy (Alpers–Huttenlocher syndrome),
adult-onset spinocerebellar ataxia, and sen-
sory nerve degeneration with dysarthria and
ophthalmoparesis (SANDO).2 3
CASE REPORTS
Two siblings of non-consanguineous
healthy Vietnamese parents were normal
until childhood (fig 1A,B).
Patient II.2, the 27-year-old male, devel-
oped from the age of 15 progressive cerebel-
lar ataxia, neuropathy, restless legs
syndrome, on two occasions a transient left
hemihypesthesia and four focal myoclonic
epileptic seizures and received lamotrigine.
He became wheelchair-bound at 22 because
of severe ataxia. By 25, he developed
dysphagia and weight loss. Muscle strength
was preserved. No external ophthalmoplegia
or cognitive deficits occurred. After discon-
tinuing lamotrigine, he exhibited grand
maux, requiring combination treatment.
He became anxious and complained of
migrainous headaches and abdominal pain.
Soon after, he died after prolonged status
epilepticus.
Lactate-ischaemia ergometry at age 20
was unremarkable. In serum, lactate and
CK (244 U/l) were mildly elevated. In CSF,
protein was elevated to 138–146 mg/dl, and
lactate was normal. Liver enzymes, echocar-
diography and abdominal ultrasound were
unremarkable. Electroneurography showed a
sensori-axonal neuropathy. Visually evoked
potentials (VEP) and vestibulogram were
pathological; funduscopy and electroretino-
gram were normal. EEG was generally
slowed with occipital 2–5/s theta/delta
waves. MRI revealed mild frontoparietal
leucoencephalopathy, mild cerebellar atro-
phy and T2-hyperintensities in the cerebellar
peduncles (fig 1A). MR spectroscopy was
normal. Muscle biopsy revealed no ragged
red and/or COX negative fibres. Screening
for mtDNA deletions in fibroblasts was
negative.
Patient II.3, the 23-year-old sister, exhib-
ited from 6 years progressively focal motor
and generalised tonic-clonic seizures,
delayed psychomotor development, sensori-
axonal neuropathy and mild tetraparesis,
and from 18 years a cerebellar syndrome. No
external ophthalmoplegia occurred. For
4 years on primidone and valproate, no
seizures and no hepatopathy were noted.
At age 23, she developed refractory status
epilepticus, remained comatose with inter-
mittent focal seizures and developed intest-
inal pseudoobstruction short before death.
Blood tests revealed normal lactate and
liver function. CSF analysis showed high
protein (264 mg/dl) and lactate levels, and
VEP were prolonged. MRI showed very mild
leucoencephalopathy, infratentorial atrophy
and T2-hyperintensities in the cerebellar
hemispheres (arrow), and during status
epilepticus transient cortical T2-hyperinten-
sities bilaterally (fig 1A).
Both patients carried the POLG1 missense
mutations, c.2284G.A (A862T) and c.
2890C.T (R964C) compound heterozy-
gously. The parents and the unaffected
brother were heterozygous (fig 1B).
To validate pathogenicity, the two muta-
tions were introduced in the equivalent
position of MIP1 gene, the POLG1 ortholo-
gue of yeast Saccharomyces cerevisiae. MIP1
A665, corresponding to POLG1 A862, was
converted to T665. MIP1 Q766, correspond-
ing to POLG1 R964, was first converted to
R766 (‘‘humanised’’) and then to C766.
Petite (MIP1 2.2% (SD 0.2)) and erythro-
mycin-resistant (EryR) mutant (MIP1 1.6
(SD 0.4)61027) frequencies served as a
measure for mtDNA deletions and mtDNA
point mutations respectively.
The mipA665T mutant was unable to
complement the Dmip1 oxidative growth
defect and to maintain mtDNA (petites
100% (0.0)*). The mip1R766C allele comple-
mented the oxidative growth defect.
However, the mip1R766C mutant showed a
twofold increase in petite (3.8% (0.3)*) and
EryR mutant (3.9 (0.4)61027*) frequencies
compared with the humanised one. The
mipA665T/mip1R766C heterozygous strain
showed a fivefold petite (4.7% (0.2)*) and
an 11-fold EryR mutant (6.8 (1.1)61027*)
frequency increase compared with homozy-
gous wildtype (petites 0.9% (0.2), EryR
mutants 0.6 (0.1)61027). The asterisk indi-
cates significance (p,0.01) compared with
MIP1 or MIP1/MIP1 in a double tailed z test.
DISCUSSION
Two siblings with phenotypically variable
presentation carried compound heterozy-
gous POLG1 polymerase domain mutations,
c.2890C.T (R964C) in exon 18 and c.
2284G.A (A862T) in exon 16 (fig 1C),
which change highly conserved amino acids.
Both mutations have been recently
reported in a compound heterozygous sub-
ject affected by juvenile onset ataxia-neuro-
pathy syndrome.3 Moreover, the R964C
mutation was detected homozygously in a
patient developing lactic acidosis after anti-
HIV therapy.4 Recombinant POLG showed
only 14% residual activity, and mtDNA
copies were decreased in lymphoblastoid
cells after supplementation with stavudine.
Furthermore, this mutation is near the
polymerase B motive, which is involved in
dNTP-binding. It was not present in 26
patients and 100 Thai control samples. We
did not detect both mutations in 100
German samples.
In yeast the substitution equivalent to
A862T of POLG1 renders Mip1 polymerase
unable to maintain mtDNA in vivo. The
substitution equivalent to R964C slightly
increases mtDNA deletions and point muta-
tions. Yeast carrying both mutations shows a
fivefold increase in mtDNA deletions and an
11-fold increase in mtDNA point mutability.
We previously showed that an increase in
mtDNA deletions was not coupled with a
significant increase in mtDNA point mut-
ability in strains carrying MIP1 recessive
mutations in heterozygous compounds.5 The
observation that in yeast the point mutability
prevails on the extended one could account
for what was observed in patients lacking
mtDNA deletions.
Disease onset was infantile with epilepsy
and mental retardation in the female and
juvenile with predominant ataxia in the male.
No external ophthalmoplegia and—very unu-
sually for recessive POLG deficiencies—no
liver involvement even after valproic acid
therapy occurred. In the brother no muscle
pathology was detected. The phenotype was
a combination of symptoms typical for Alpers
syndrome (therapy-resistant epilepsy, stroke-
like episodes, but without hepatopathy and
blindness) and SANDO (sensori-axonal neu-
ropathy, dysarthria but no ophthalmopar-
esis). The variability raises the possibility of
influential epigenetic factors.
The dramatic deterioration after status
epilepticus stresses the importance of early
anticonvulsant therapy escalation even if
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seizures are focal and rare. Both patients
eventually received coenzyme Q10 and crea-
tine, but therapeutic effects remain uncertain.
Concerning MRI in POLG disease, there
are reports of cerebrocortical and cerebellar
atrophy, leucoencephalopathy, cortical
hyperintensities and focal lesions, partially
reversible, in thalami, basal ganglia, occipital
poles and in cerebellar hemispheres.2
Interestingly, both siblings displayed sym-
metrical cerebellar T2-hyperintensities.
Leucoencephalopathy was mild. Cerebellar
atrophy was more prominent in the female,
not correlating with severity of ataxia. Her
transient precentral cortical T2-hyperinten-
sities most likely represent postictal vaso-
genic oedema.
Carrier frequency studies suggest that the
disease is underdiagnosed as having an
A467T mutation frequency of 0.69% in
British and 0.19% in German controls.2
Taken together, our cases highlight the
importance of genetic testing for POLG
disorders also in the absence of external
ophthalmoplegia, typical muscle pathology,
valproate toxicity and hepatic pathology.
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Figure 1 (A) Clinical course of the sister (II.3) and the brother (II.2) with MRI of the sister revealing cortical lesions and cerebellar T2-hyperintensities
(arrow) and the brother’s MRI showing leucoencephalopathy and cerebellar T2-hyperintensities. (B) Family pedigree with polymerase c 1 (POLG1)
mutations. Squares represent males, circles females, filled symbols affected and slashed symbols deceased individuals. (C) Mutant residues in POLG1
and amino-acid alignment showing evolutionary conservation of altered residues.
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